Eris Lifesciences (NSE:ERIS) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:ERIS Eris Lifesciences Ltd NSE:ERIS
91 GF Score
Price ₹1,459.00
GF Value ₹1,642.12
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eris Lifesciences Research & Development?

Eris Lifesciences NSE:ERIS -0.50% 91 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:ERIS with a GF Score™ of 91/100 and a GF Value™ of ₹1,642.12 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Eris Lifesciences's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Eris Lifesciences  (NSE:ERIS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Eris Lifesciences Research & Development Related Terms

Eris Lifesciences Research & Development Historical Data

* Premium members only.

The historical data trend for Eris Lifesciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eris Lifesciences Research & Development Chart

Eris Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 327.38 61.00 57.20 24.40 0.00

Eris Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:ERIS
91GF Score
Eris Lifesciences Ltd NSE:ERIS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eris Lifesciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Eris Lifesciences (NSE:ERIS) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Eris Lifesciences and its competitors.
Is Eris Lifesciences' Research & Development too high?
Eris Lifesciences' current Research & Development is ₹0 Mil. Overall, Eris Lifesciences has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' Research & Development compare to ZTS and UTHR?
Eris Lifesciences' Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Eris Lifesciences and its competitors. Eris Lifesciences's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (NSE:ERIS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,642.12, compared to a current price of ₹1,459.00 — trading 11.2% below its estimated fair value. The current Research & Development is ₹0 Mil. Eris Lifesciences' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Eris Lifesciences (NSE:ERIS), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eris Lifesciences (NSE:ERIS) Overvalued in 2026?

Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued. The current stock price of ₹1,459.00 is trading 11.2% below its estimated GF Value™ of ₹1,642.12. GuruFocus considers Eris Lifesciences to be Modestly Undervalued.

Key valuation signals for NSE:ERIS:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹1,642.12 vs. price of ₹1,459.00 (11.2% below fair value)
  • GF Score™: 91/100 with 6 warning signs

No single metric tells the full story. See the NSE:ERIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eris Lifesciences Business Description

Other Exchanges 540596:India
Address Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
91GF Score

Get the complete analysis for NSE:ERIS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,459.00
Price
₹1,642.12
GF Value